Fig. 5
Pharmacokinetics and biodistribution of [125I]RmAb158-scFv8D3 following chronic antibody treatment. A Study design: 7-month-old AppNL−G−F mice were depleted of CD4+ T cells by injection of anti-CD4 antibody (167 nmol/kg), followed by weekly i.p. injections of RmAb158-scFv8D3 (6.4 or 32 nmol/kg) or RmAb158 (32 nmol/kg) during 8 weeks. Three days after the last injection, a diagnostic tracer dose (0.6 nmol/kg) of [125I]RmAb158-scFv8D3 was administered i.v. Blood (B) and plasma (C) pharmacokinetics of [125I]RmAb158-scFv8D3 with inserts displaying total exposure over 72 h (area under the curve – AUC). D [125I]RmAb158-scFv8D3 retention in the cortex, hippocampus, cerebellum, and peripheral organs liver, spleen, and thyroid. E [125I]RmAb158-scFv8D3 concentration, individually adjusted for total exposure (plasma AUC) in the cortex, hippocampus, cerebellum, and peripheral organs liver, spleen, and thyroid. Values are mean and SD. A was created with BioRender